[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_5049 

# __Challenges in scalability, manufacturing costs, and accessibility of covid-19 vaccines__

## Articles mentionning the risk

* [Ayub_graphene-based_2021](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_404.md)

## Mitigations of this risk

* [Investment in scalable production facilities, cost reduction strategies, and equitable distribution plans](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_6922.md)

## Name of the risk

Limited availability of vaccines leading to prolonged pandemic and increased transmission of the virus

## People affected by this risk

* [Especially in underprivileged regions](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_278.md)
* [Global population](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_4251.md)

## Stakeholders who can mitigate this risk

* [Global health organizations](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_47.md)
* [Governments](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_857.md)
* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)

## Technologies linked to the risk

* [Bioprocessing technologies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_6129.md)
* [Manufacturing automation](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_6130.md)
* [Mrna vaccine platforms](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_6131.md)

## This Risk belongs to this RiskGroup

* [Economic risks](https://github.com/mm80843/T3.5/blob/pages/RiskGroup/PBN__RiskGroup_5.md)

## This Risk belongs to this RiskSubgroup

* [Pandemic impact on markets](https://github.com/mm80843/T3.5/blob/pages/RiskSubgroup/PBN__RiskSubgroup_34.md)

